Open AccessMetabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases
Author(s) -
Brandon Wyman,
András Perl
Publication year - 2020
Publication title -
current opinion in rheumatology/current opinion in rheumatology, with evaluated medline
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.452
H-Index - 112
eISSN - 1080-8175
pISSN - 1040-8711
DOI - 10.1097/bor.0000000000000687
Subject(s) - pi3k/akt/mtor pathway , immunology , immune system , inflammation , proinflammatory cytokine , medicine , autoimmunity , mechanistic target of rapamycin , cancer research , biology , signal transduction , microbiology and biotechnology
The cause of autoimmune diseases remains incompletely understood. Here, we highlight recent advances in the role of proinflammatory metabolic pathways in autoimmune disease, including treatment with antioxidants and mechanistic target of rapamycin (mTOR) inhibitors.